July 20, 2012

Louis B. Jacques, MD
Director, Coverage and Analysis Group
Centers for Medicare & Medicaid Services
7500 Security Blvd
Baltimore, MD 21244

Via Electronic Delivery

RE: National Oncologic PET Registry (NOPR) Working Group Request for Reconsideration of NCA for Positron Emission Tomography (FDG) for Oncologic Indications (CAG-00181R)

Dear Dr. Jacques:

As the Co-chairs of the National Oncologic PET Registry (NOPR) Working Group, we respectfully request a formal reconsideration of the Centers for Medicare & Medicaid Services (CMS) National Coverage Analyses (NCA) on Positron Emission Tomography (FDG) for oncologic indications (CAG-00181R). In particular, we are writing with the specific request to end the remaining prospective data collection requirements under Coverage with Evidence Development (CED) for all oncology indications for FDG-PET imaging, and revise the National Coverage Determination (NCD) for PET Scans, Manual Section 220.6, accordingly. The NOPR is sponsored by the World Molecular Imaging Society (WMIS) (formerly the Academy of Molecular Imaging (AMI)) and managed by the American College of Radiology (ACR).

We believe that both CMS and Medicare beneficiaries have benefited from the NOPR’s seven years of experience in implementing, improving, and operating a large-scale CED study. As discussed more fully below, we strongly believe that the purpose of CED for FDG-PET for

---

1 National Coverage Analysis (NCA) for Positron Emission Tomography (CAG-00181N), available at https://www.cms.gov/medicare-coverage-database/details/nca-details.aspx?NCAId=92&ver=19&NcaName=Positron+Emission+Tomography+%7C+x28FDG%29+x29+for+Brain%2c+Cervical%2c+Ovarian%2c+Pancreatic%2c+Small+Cell+Lung%2c+and+Testicular+Cancers&bc=BEAAAAAAA

oncologic indications has been fulfilled, as the NOPR has demonstrated through its published research of the CED evidence that PET is both reasonable and necessary for subsequent treatment strategy of oncologic indications. While CMS ended the CED requirements in 2009 for initial treatment strategy of most oncologic indications, CMS continued to require CED for subsequent treatment strategy evaluations for many cancers types. In light of the robust NOPR data collected since 2009, we are now convinced that there remains no clinical need to continue CED data collection for FDG-PET oncologic indications. Our recent May 2012 *Journal of Nuclear Medicine* article (attached) comparing the NOPR 2006 and 2009 cohorts — discussed in more detail below — further confirms this view.3

In sum, we urge CMS to review the existing NCD in light of the published evidence, which we believe supports our conclusion that the remaining CED restrictions pertaining to FDG-PET for oncologic indications should be removed.4

I. **Background and Accomplishments of NOPR and CED**

Since 2001, FDG PET has been covered by CMS across the cancer management continuum (excluding treatment monitoring and surveillance) for non–small cell lung, colorectal, esophageal, and head and neck cancers, as well as melanoma and lymphoma.5 In addition, for more narrowly defined indications, PET was also covered by CMS for breast, thyroid, and cervical cancers.6 However, as of 2005, one fourth of Medicare beneficiaries who developed cancer had a non-covered type of cancer (e.g., pancreatic cancer or endometrial cancer).7 For these less common cancer types, policymakers and the oncology community recognized it was unlikely that sufficient clinical evidence would be developed to inform a PET coverage decision on a cancer-by-cancer and indication-by-indication basis (each of which requiring a new coverage decision by CMS). As a result, the NOPR was established as part of the CMS CED mechanism.8

The NOPR was one of the first CED projects undertaken by CMS. From the beginning, the WMIS and the ACR—the organizations developing the NOPR—worked closely with CMS staff on design and implementation of all aspects of the NOPR. The NOPR was launched as a

4 This reconsideration request does not address specific tumors types that have been previously non-covered including initial anti-tumor treatment in breast cancer; regional lymph nodes in melanoma; and initial anti-tumor treatment strategy in Medicare beneficiaries who have adenocarcinoma of the prostate.
clinical study in 2006, in response to a CMS proposal to expand coverage for $^{18}$F-fluorodeoxyglucose positron emission tomography (FDG-PET) to cancers and indications not previously eligible for Medicare reimbursement. CED allowed Medicare beneficiaries with less common cancer types to have equal access to PET in order to inform clinical management decisions, in conjunction with prospective data collection within the NOPR. The primary objective of the NOPR was to measure the impact of PET on the referring physician’s intended patient management by collecting questionnaire data before PET and again after the PET results are available for decision making.

Under the CED framework, Medicare coverage for these cancers is contingent on submission of clinical data to a registry. Since 2006, the NOPR has implemented this registry and shared the resulting data with CMS. In the NOPR’s first phase, from May 2006 through April 2009 (known as “NOPR 2006”), approximately 133,000 PET scans from nearly 1,900 PET facilities—representing more than 90% of all U.S. PET sites—were covered by Medicare via the NOPR. On April 3, 2009, CMS substantially revised its coverage policy for cancer-related PET. For oncologic indications (other than prostate cancer), FDG-PET became a universally available if needed as a one-time covered service to determine the location and tumor extent for initial treatment planning. However, CMS made much more conservative changes in its coverage of FDG-PET used for planning subsequent treatment strategy: new coverage of this type was offered only to patients with ovarian and cervical cancers, and myeloma. As a result, for numerous infrequent cancer types (which together represent about 10% of incident cases in the elderly), FDG-PET outside of initial management is covered by CMS only pursuant to CED.

---

12 Id.
Since April 2009, complete data have been submitted for approximately 103,000 additional scans undertaken under this new phase of the NOPR (known as “NOPR 2009”).

II. Evidence from the NOPR

To date, NOPR investigators have published seven clinical studies in the peer-reviewed scientific literature, with several more in preparation. These include reports on the impact of FDG-PET on intended patient management, including analyses of data collected during the first year of operation, 2-year data restricted to patients with confirmed cancer and analyzed with respect to specific cancer type, data related to the use of FDG-PET as an adjunct for treatment monitoring, and data for dedicated oncologic brain PET. The common result of these different analyses was that the results of PET were associated with a reported change in intended management in about one third of cases, with minimal differences across analyses by cancer type or indication that were not clinically important. As noted above, this research, in part, led CMS to revise its coverage policy for cancer-related PET, authorizing FDG-PET for all oncologic indications (other than prostate cancer) for initial treatment planning.

Our most recent analysis offers a comprehensive comparison of the cancer types common to NOPR 2006 and NOPR 2009 cohorts. We assessed NOPR data for subsequent treatment strategy PET scans for bladder, kidney, pancreas, prostate, stomach, small cell lung, uterine, and all other cancers that required data collection in both NOPR 2006 and NOPR 2009. We compared clinical profiles and changes in intended management by interval (before or after April 2009) for PET scans performed for restaging or suspected recurrence (2006, n = 30,911; 2009, n = 54,747) or for chemotherapy monitoring (2006, n = 10,234; 2009, n = 15,611). We hypothesized that there would be no clinically meaningful differences between the NOPR 2006 and NOPR 2009 cohorts for these cancer types, either individually or in aggregate.

Our research supported strongly this hypothesis. The analysis indicated that when used for subsequent treatment planning, a NOPR FDG-PET scan was associated with about a 35% change in intended management. The observed intended management change was minimally different between cancer types, time periods (before or after 2009), and age (when comparing younger, disabled Medicare beneficiaries with the traditional Medicare population aged 65 years.

---

and over). Our analysis thus indicates wide-ranging similarities across a broad spectrum of tumor types that are still being included in the CED program under NOPR 2009. The similarities across cancer subtypes were also robust to the study period (2006 vs. 2009) and the indication for which a FDG-PET scan was ordered.

Moreover, we found little indication—either from the time series trend or from the type-specific data—that simply expanding the volume of scan data from further patients will provide much additional clinically meaningful insight into the impact of PET on intended management of these patients. An additional key finding was that when the NOPR 2009 data are compared with our multiple prior publications on the NOPR 2006 cohort, few (if any) impactful differences are evident between those types of patients (and cancers) now covered without CED and those remaining under the CED registry protocol. In sum, these results strongly suggest it is unlikely that new useful information will be obtained by extending the coverage of certain cancer types and indications only under CED.

NOPR has been successful in meeting the goal for which it was established: providing clear data on the previously little-researched question of whether the impact of FDG-PET on different cancers would be similar in actual clinical practice in the Medicare population. Even with less common cancers, NOPR has produced evidence that the impact of FDG-PET on physician decision making for patient management seems remarkably uniform. Although there remain important open questions concerning PET—such as how PET should be most effectively sequenced with other imaging resources in patient care pathways—we believe such research would require a very different vehicle than the NOPR, and thus that there would be little benefit to such research in continuing to maintain the existing CED requirements for oncologic FDG-PET.

III. Conclusion and Reconsideration Request

On behalf of the NOPR, we appreciate the assistance and support that CMS has provided to the NOPR over the past eight years. We believe that the evidence-based conclusions reached from multiple analyses of the extensive NOPR data set strongly support the reconsideration and removal of the data collection requirement under CED in the context of oncologic FDG-PET.20

20 This request does not address indications that are non-covered under prior NCD, including 1) Breast: noncovered for diagnosis and/or initial staging of axillary lymph nodes; 2) prostate: noncovered for initial treatment strategy; and 3) Melanoma: noncovered for initial staging of regional lymph nodes.
We look forward to working with CMS to provide any additional information that would be valuable in supporting our conclusion that the CED restrictions on FDG-PET for oncologic indications have served their intended purpose of demonstrating the reasonable and necessary nature of PET, and thus can be ended without detriment to either the Medicare program or to its beneficiaries.

Sincerely,

Bruce E. Hillner, M.D., Chair

Barry A. Siegel, M.D., Co-chair

Anthony F. Shields, M.D., Co-chair
Impact of $^{18}$F-FDG PET Used After Initial Treatment of Cancer: Comparison of the National Oncologic PET Registry 2006 and 2009 Cohorts

Bruce E. Hillner1, Barry A. Siegel2, Lucy Hanna3, Anthony F. Shields4, Fenghai Duan3, Ilana F. Gareen3, Bruce Quinn5, and R. Edward Coleman6

1Department of Internal Medicine and the Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia; 2Division of Nuclear Medicine, Mallinckrodt Institute of Radiology and the Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri; 4Center for Statistical Sciences, Brown University, Providence, Rhode Island; 4Karmanos Cancer Institute, Wayne State University, Detroit, Michigan; 5Foley Hoag LLC, Boston, Massachusetts; and 6Department of Radiology, Duke University School of Medicine, Durham, North Carolina

Since 2006, the National Oncologic PET Registry has collected prospective data on $^{18}$F-FDG PET performed for cancer indications in Medicare beneficiaries under the coverage-with-evidence-development (CED) policy of the Centers for Medicare & Medicaid Services. In April 2009, coverage for PET performed to inform the initial treatment strategy of most solid tumors was expanded by the Centers for Medicare & Medicaid Services, but they continued to require CED for subsequent treatment strategy evaluations for many cancers. Methods: For all years, we assessed National Oncologic PET Registry data for bladder, kidney, pancreas, prostate, stomach, small cell lung, uterine, and all other cancers that required CED. We compared clinical profiles and changes in intended management by interval (before or after April 2009, designated as the 2006 and 2009 cohorts) for PET scans performed for restaging or suspected recurrence (2006, n = 30,911; 2009, n = 54,747) or for chemotherapy monitoring (2006, n = 10,234; 2009, n = 15,611). Results: There were slight differences between time periods but little difference by cancer type or patient age within a time period. For restaging or suspected recurrence, comparing the 2006 and 2009 cohorts, total change in intended management for all cancer types was about 33% in those younger than 65 y and about 35% in those older than 65 y (range by cancer type, 31%-41%). The referring physician impression of disease extent (restaging) or prognosis (chemotherapy monitoring) after PET was similar between cohorts. In the 2009 cohort, PET for chemotherapy monitoring was associated with a 25% increase in plans to continue therapy and a complementary decline in plans to adjust therapy. The greatest management impact of PET was during chemotherapy monitoring in the 2009 cohort, where a post-PET prognosis judged to be worse than before PET was associated with a plan to discontinue therapy in 90% and to change to a different therapy in 65%. Conclusion: Our data demonstrate a similar impact of PET on planned management of cancer patients before and after the 2009 expansion of coverage. These results strongly suggest it is unlikely that new useful information will be obtained by extending the coverage of certain cancer types and indications only under CED. Future research on advanced imaging in the management of patients with cancer should focus on optimal sequencing and frequency of PET and other imaging modalities.

Key Words: positron emission tomography; patient registry; multiple cancer types

DOI: 10.2967/jnumed.112.103911

Over the last 15 y, the Centers for Medicare & Medicaid Services (CMS) has sequentially expanded the coverage of PET and integrated PET/CT with $^{18}$F-FDG for Medicare beneficiaries on a cancer-by-cancer and indication-by-indication basis (1). Since 2001, $^{18}$F-FDG PET has been covered across the cancer management continuum (excluding treatment monitoring and surveillance) for non–small cell lung, colorectal, esophageal, and head and neck cancers, as well as melanoma and lymphoma. In addition, for more narrowly defined indications, PET was also covered for breast, thyroid, and cervical cancers (2). However, as of 2005, one fourth of Medicare beneficiaries who developed cancer had a noncovered type of cancer (e.g., pancreatic cancer or endometrial cancer) (3). For these less common cancer types, policymakers and the oncology community recognized it was unlikely that sufficient clinical evidence would be developed to inform a PET coverage decision on a cancer-by-cancer and indication-by-indication basis, each requiring a new coverage decision by CMS. Therefore, in 2005, CMS announced a new coverage mechanism for the otherwise noncovered cancers and indications under its coverage-with-evidence-development (CED) policy (4,5). In response to the CED requirements, the National Oncologic PET Registry (NOPR) was created under the
sponsorship of the Academy of Molecular Imaging. The NOPR opened for accrual in 2006, thereby allowing Medicare beneficiaries with these less common cancer types to have equal access to PET in order to inform clinical management decisions, in conjunction with prospective data collection within the registry (5,6). The primary objective of the NOPR is to measure the impact of PET on the referring physicians’ intended patient management by collecting questionnaire data before PET and again after the PET results are available for decision making.

Previously, we have reported NOPR findings on the impact of PET on intended patient management, including analyses of data collected during the first year of operation, 2-y data restricted to patients with confirmed cancer, data related to the use of PET as an adjunct for treatment monitoring, and data for dedicated brain PET (7–10). The common result of these different analyses was that the results of PET were associated with a reported change in intended management in about one third of cases, with minimal clinically important differences across analyses by cancer type or indication.

In part as a result of these publications, in April 2009 CMS substantially revised its coverage policy for cancer-related PET (1). For all solid tumors (other than prostate cancer), PET became a universally covered one-time service to determine the location and tumor extent for initial treatment planning. However, CMS made much more conservative changes in its coverage of PET used for planning subsequent treatment strategy: new coverage of this type was offered only to patients with ovarian and cervical cancers, and myeloma. As a result, for a long list of infrequent cancer types, which together represent about 10% of incident cases in the elderly, PET outside of initial management continued to be covered by CMS only under the CED program.

In this report, we compare the impact of PET on intended management for the 7 most common cancer types that remained in NOPR after 2009 (bladder, kidney, pancreas, prostate, small cell lung, stomach, and uterus) and an aggregation of all other types for the periods before and after April 2009 (designated NOPR 2006 and NOPR 2009, respectively) when the use was categorized as subsequent treatment planning, including restaging or detection of suspected recurrence (henceforth collectively designated as restaging) or treatment monitoring. We hypothesized that there would be no clinically meaningful differences between the NOPR 2006 and NOPR 2009 cohorts for these cancer types individually or in aggregate.

MATERIALS AND METHODS

NOPR Design and Workflow

The NOPR is a prospective data registry that collects information from the PET facility, from the physician requesting the PET scan, and from the interpreting physician’s PET report. Detailed descriptions of NOPR operations, human subject protection procedures, and results for the impact of PET on physicians’ intended management were previously reported (7–10). Both patient and physician consent were required for the research use of their data. The research conducted using NOPR data is registered as NCT00868582 at ClinicalTrials.gov.

In brief, the PET facility is responsible for collecting referring physician responses on a pre-PET form and on a post-PET form. The pre-PET form collects the specific testing indication, the patient’s cancer type, a working stage assessment, the performance status, and the referring physician’s management plans if PET were unavailable. After PET completion, the PET facility uploads the PET report to the database. The final step is the completion of the post-PET form by the referring physician to record the management plan chosen in light of the PET findings.

Endpoints and Analysis Plan

For all indications, the primary endpoint was the impact of PET on physicians’ intended management dichotomized as either “treatment” (e.g., surgery, chemotherapy, radiation, or other active treatment for the cancer, alone or in combination) or “nontreatment” (e.g., observation, alternative imaging, or other noninvasive testing, biopsy, or supportive care). A “change in management” was defined as a switch from treatment to nontreatment or vice versa. Our prior reports found that PET led to a change in intended management in 35%–40% of cases, with a switch from treatment to nontreatment being 3-fold more likely than the converse (8,9).

We also calculated an “imaging-adjusted impact” score, in which cases were excluded from the numerator when the plan before PET was another type of imaging and the plan after PET was treatment. These cases were, however, included in the denominator in calculating the frequency of a management change (8). We believe this method reflects a lower boundary for the impact of PET on intended management, because it assumes that the impact of PET would be the same as the alternative mode of imaging.

Treatment monitoring refers to the use of PET to monitor tumor response to treatment during a planned course of therapy (usually when a change in therapy is being considered) (7). Since the purpose of scanning done for treatment monitoring differs from that done for restaging, additional data were collected on the pre-PET questionnaire for this indication, including treatment goal (curative vs. palliative) and estimated prognosis. Beginning in 2009, further additions to the pre-PET form included duration of treatment before imaging and impression of response to date. The specific drugs used and further details of preceding treatment (if metastatic disease) were beyond the scope of the registry. Given that the patient was currently receiving therapy, the endpoints were continuing, modifying, switching, or stopping therapy, as well as first performing biopsy or other imaging. For this report, we restricted our assessment to chemotherapy monitoring.

NOPR 2006–2011 Accrual

NOPR 2006 opened for patient accrual on May 8, 2006, and closed on April 3, 2009. Nearly 1,900 PET facilities representing more than 90% of all U.S. PET sites participated. Complete data were submitted for approximately 133,000 scans. NOPR 2009 opened on April 6, 2009. As of November 30, 2011, complete data were submitted for about 72,000 scans. The research dataset, which consists of cases with both patient and referring physician consent for research, represented approximately 88% of scans and varied minimally from year to year.
RESULTS

Clinical Characteristics

Table 1 shows the clinical characteristics of NOPR participants stratified by time interval, testing indication, and patient age in aggregate for all cancer types. Patients under 65 y old (disabled) comprised about 10% of participants, with a slight increase in NOPR 2009. The average age of the Medicare elderly participants was 75.0 y, stable from year to year, and similar for restaging and chemotherapy monitoring. PET studies were performed with PET/CT scanners in 90% and 97% of NOPR 2006 and NOPR 2009 cases, respectively.

Patients whose clinical indication for testing was chemotherapy monitoring differed from other patients. In the chemotherapy monitoring cohort, 17% of patients had Eastern Cooperative Oncology Group performance status scores of 2, 3, or 4. When the indication for testing was restaging, performance status scores of 2–4 were reported only 12% of the time. Performance status scores did not differ by age (greater or less than 65).

Patients tested for restaging versus chemotherapy monitoring also differed in the referring physician summary stage. For the restaging indication, 45%–50% of patients were judged to have either no or a low probability of recurrence. In the chemotherapy cohort, only about 14% were judged to have no or a low probability of recurrence. The frequency of metastatic disease was 35%–40% in the restaging cohorts versus 63%–66% of those having chemotherapy monitoring. There were minimal differences in the distribution within a testing indication by age or time period.

In 2009, NOPR added questions on the duration of chemotherapy given before the PET study. About 6% of patients underwent PET after less than 1 mo of therapy, 32% after 1–3 mo, and 28% after 3–6 mo; about one third had already received more than 6 mo of treatment when the PET was performed.

After the PET study, referring physicians were asked 2 related, but slightly different, questions regarding disease burden or prognosis. Specifically, after PET for restaging, physicians were asked to record their impression of the extent of disease (less extensive, unchanged, or more extensive than estimated before PET). After PET for chemotherapy monitoring, physicians were asked to record the change in prognosis (better, unchanged, or worse) in light of the PET findings.

Physicians changed their estimates of disease extent about two thirds of the time after PET for restaging. Disease extent was judged to be less than anticipated in 35%–37%, unchanged in 33%–35%, and more extensive in 30%. These results were similar in the NOPR 2006 and 2009 cohorts.

The physician’s prognosis after PET for chemotherapy monitoring also changed about 70% of the time and was not meaningfully different between the 2006 and 2009 cohorts. A better prognosis than anticipated occurred in about 40%, no change in 31%, and a worse prognosis in 29%. Intra-category differences between the time periods were less than 2%.

Restaging or Suspected Recurrences

Table 2 shows the impact of PET on intended management for restaging for all cancer types stratified by time interval and age. The overall frequency of management change was calculated as the sum of a change from a non-treatment plan (predominantly other imaging, if PET were not available) to treatment and from treatment to nontreatment (predominantly to watching or supportive care).

The dominant impact was a change from nontreatment to treatment. In the 2009 cohort about 2% more scans led to a change in intended management from nontreatment to treatment than in the 2006 cohort (30% vs. 28%). The reverse pattern, changing from treatment to nontreatment, declined by 2% (from ~8% to ~6%) from 2006 to 2009. The overall impact of 35% was essentially unchanged in 2006 and 2009 ($\chi^2 = 0.23, P = 0.62$). In each period, the impact was about 2% less in those less than 65 y old versus more than 65 y old.

Table 3 shows the changes in intended management associated with PET when used in restaging stratified by cancer type and testing interval in patients over age 65 y. An overall pattern of a 4- to 5-fold larger change from non-treatment to treatment than the converse was seen. For all cancer types except prostate cancer, there was no difference between time cohorts in the impact of PET on intended management.

The imaging-adjusted impact, the more conservative estimate of the change in intended management, is shown in Tables 2 and 3. The overall imaging-adjusted impact was slightly higher in NOPR 2006 than in NOPR 2009 (15.1%...
vs. 12.5%) and was similar in both age groups within a time period. Table 3 shows for patients over 65 y old that the imaging-adjusted impact stratified by cancer type and time interval showed the same temporal trends.

Chemotherapy Monitoring

Table 4 shows the impact of PET on intended management during chemotherapy monitoring stratified by time interval and cancer types. There is a distinct change in intended management by time interval but nonmeaningful differences within time intervals. For all cancer types combined and for each individually, continuing the current chemotherapy (type, dose, and schedule) was more frequent in NOPR 2009 than in NOPR 2006 (46.9% in 2009 vs. 34.7% in 2006 \(\chi^2 = 253, P < 0.0001\)). The increased frequency of continuing the current chemotherapy was greater in patients with bladder, prostate, and small cell lung cancer (∼17%).

The frequency of switching to another type of chemotherapy clustered at around 25% of cases and minimally differed by cancer type or time period. Stopping chemotherapy treatment and switching to watching or supportive care declined slightly in all cancer types except for pancreas in NOPR 2009. Stopping therapy was most common in bladder and small cell lung cancer at about 20%. The increase in plans to continue the current chemotherapy in 2009 was

### Table 1: Clinical Characteristics of NOPR Cohorts

<table>
<thead>
<tr>
<th>NOPR interval cohort</th>
<th>Restaging or suspected recurrence</th>
<th>Chemotherapy monitoring, all ages</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Age &lt; 65 y</td>
<td>Age &gt; 65 y</td>
</tr>
<tr>
<td>2006*</td>
<td>2009*</td>
<td>2006</td>
</tr>
<tr>
<td>Patients (n)</td>
<td>3,051</td>
<td>5,916</td>
</tr>
<tr>
<td>Age (y)</td>
<td>Mean 53.7</td>
<td>55.0</td>
</tr>
<tr>
<td></td>
<td>25%–75% range 49–61</td>
<td>51–62</td>
</tr>
</tbody>
</table>
| Eastern Cooperative Oncology Group Performance Status
| Asymptomatic; performance status = 0 (%) | 986 (32.3) | 2,107 (35.6) | 10,433 (39.3) | 18,290 (39.2) | 2,197 (21.5) | 2,929 (18.8) |
| Symptomatic, fully ambulatory; performance status = 1 (%) | 1,601 (52.5) | 3,108 (52.5) | 12,835 (48.3) | 23,213 (49.7) | 6,226 (60.8) | 9,996 (64.0) |
| Performance status = 2, 3, or 4 (%) | 464 (15.2) | 701 (11.8) | 3,283 (12.4) | 5,179 (11.1) | 1,811 (17.7) | 2,686 (17.2) |
| Summary stage†
| No or low probability of disease recurrence | 1,568 (51.4) | 3,190 (53.9) | 12,283 (46.3) | 21,834 (46.8) | 1,514 (14.8) | 2,179 (14.0) |
| Local or nodal recurrence | 392 (12.8) | 651 (11.0) | 3,546 (13.4) | 5,793 (12.4) | 1,332 (13.0) | 1,736 (11.1) |
| Metastatic disease | 1,091 (35.8) | 2,075 (35.1) | 10,721 (40.4) | 19,055 (40.8) | 6,431 (62.8) | 10,323 (66.1) |
| Stage unknown | – | – | – | – | 957 (9.4) | 1,373 (8.8) |

†Summary stage for restaging or suspected recurrence was collected before PET. Stage for chemotherapy monitoring is after PET. Data in parentheses are percentages.

### Table 2: Impact of PET on Intended Management for Restaging

<table>
<thead>
<tr>
<th>Time period</th>
<th>Age (y)</th>
<th>Patients (n)</th>
<th>Nontreatment to treatment (%)</th>
<th>Treatment to nontreatment (%)</th>
<th>Change in management (%)</th>
<th>95% confidence interval</th>
<th>Imaging-adjusted impact (%)*</th>
<th>95% confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>&lt;65</td>
<td>3,051</td>
<td>25.7</td>
<td>8.0</td>
<td>33.7</td>
<td>32.0–35.4</td>
<td>15.2</td>
<td>14.0–16.5</td>
</tr>
<tr>
<td></td>
<td>≥65</td>
<td>27,860</td>
<td>27.7</td>
<td>8.1</td>
<td>35.8</td>
<td>35.3–36.4</td>
<td>15.1</td>
<td>14.7–15.6</td>
</tr>
<tr>
<td></td>
<td>All ages</td>
<td>30,911</td>
<td>27.5</td>
<td>8.1</td>
<td>35.6</td>
<td>35.1–36.2</td>
<td>15.1</td>
<td>14.7–15.5</td>
</tr>
<tr>
<td>2009</td>
<td>&lt;65</td>
<td>5,916</td>
<td>27.5</td>
<td>5.9</td>
<td>33.4</td>
<td>32.2–34.7</td>
<td>12.1</td>
<td>11.2–12.9</td>
</tr>
<tr>
<td></td>
<td>≥65</td>
<td>48,831</td>
<td>29.9</td>
<td>6.0</td>
<td>35.9</td>
<td>35.4–36.3</td>
<td>12.6</td>
<td>12.3–12.9</td>
</tr>
<tr>
<td></td>
<td>All ages</td>
<td>54,747</td>
<td>29.6</td>
<td>6.0</td>
<td>35.6</td>
<td>35.2–36.0</td>
<td>12.6</td>
<td>12.3–12.8</td>
</tr>
</tbody>
</table>

*Imaging-adjusted impact: No benefit from PET was assumed for cases with a plan before PET of alternative imaging.
almost balanced by the concurrent decrease in plans to adjust the dose or schedule of the current chemotherapy (14.6% vs. 6.3%, NOPR 2006 vs. 2009).

Prognostic Estimate and Change in Chemotherapy Monitoring Plan

Figure 1 shows the intended chemotherapy plans after PET in relationship to the change in prognosis (better, no change, or worse) indicated by the PET findings and the time interval.

If the post-PET prognostic impression was better or unchanged, continuing the same chemotherapy dose and schedule was the dominant plan. The frequency of continuing the current therapy was greater in NOPR 2009 than in NOPR 2006 (66% vs. 44%). However, if the prognosis was judged to be worse, about two thirds of patients would

TABLE 3
Impact of PET on Intended Management for Restaging in Patients Older Than 65 Years

<table>
<thead>
<tr>
<th>Cancer</th>
<th>Time period</th>
<th>Patients (n)</th>
<th>Nontreatment to treatment (%)</th>
<th>Treatment to nontreatment (%)</th>
<th>Change in management (%)</th>
<th>95% confidence interval</th>
<th>Imaging-adjusted impact (%)</th>
<th>95% confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bladder</td>
<td>2006</td>
<td>3,322</td>
<td>28.2</td>
<td>7.9</td>
<td>36.1</td>
<td>34.5–37.8</td>
<td>16.0</td>
<td>14.8–17.3</td>
</tr>
<tr>
<td></td>
<td>2009</td>
<td>5,539</td>
<td>29.4</td>
<td>5.9</td>
<td>35.3</td>
<td>34.0–36.6</td>
<td>12.8</td>
<td>11.9–13.7</td>
</tr>
<tr>
<td>Kidney</td>
<td>2006</td>
<td>3,068</td>
<td>24.8</td>
<td>7.3</td>
<td>32.1</td>
<td>30.5–33.8</td>
<td>14.4</td>
<td>13.2–15.7</td>
</tr>
<tr>
<td></td>
<td>2009</td>
<td>4,708</td>
<td>27.2</td>
<td>5.8</td>
<td>33.0</td>
<td>31.6–34.4</td>
<td>12.7</td>
<td>11.7–13.6</td>
</tr>
<tr>
<td>Pancreas</td>
<td>2006</td>
<td>2,876</td>
<td>31.6</td>
<td>8.6</td>
<td>40.2</td>
<td>38.4–42.0</td>
<td>16.5</td>
<td>15.1–17.9</td>
</tr>
<tr>
<td></td>
<td>2009</td>
<td>4,238</td>
<td>34.2</td>
<td>5.8</td>
<td>40.0</td>
<td>38.6–41.5</td>
<td>12.9</td>
<td>11.9–13.9</td>
</tr>
<tr>
<td>Prostate</td>
<td>2006</td>
<td>4,856</td>
<td>27.7</td>
<td>10.2</td>
<td>37.8</td>
<td>36.5–39.2</td>
<td>16.0</td>
<td>15.0–17.0</td>
</tr>
<tr>
<td></td>
<td>2009</td>
<td>5,465</td>
<td>34.4</td>
<td>7.0</td>
<td>41.4</td>
<td>40.0–42.7</td>
<td>13.4</td>
<td>12.5–14.3</td>
</tr>
<tr>
<td>Small cell lung</td>
<td>2006</td>
<td>2,810</td>
<td>33.0</td>
<td>7.8</td>
<td>40.7</td>
<td>38.9–42.6</td>
<td>15.2</td>
<td>13.9–16.5</td>
</tr>
<tr>
<td></td>
<td>2009</td>
<td>5,403</td>
<td>34.4</td>
<td>5.8</td>
<td>40.2</td>
<td>38.9–41.5</td>
<td>12.7</td>
<td>11.8–13.6</td>
</tr>
<tr>
<td>Stomach</td>
<td>2006</td>
<td>2,281</td>
<td>23.1</td>
<td>8.1</td>
<td>31.2</td>
<td>29.3–33.1</td>
<td>12.9</td>
<td>11.5–14.3</td>
</tr>
<tr>
<td></td>
<td>2009</td>
<td>3,162</td>
<td>26.0</td>
<td>6.4</td>
<td>32.4</td>
<td>30.8–34.0</td>
<td>11.9</td>
<td>10.9–13.0</td>
</tr>
<tr>
<td>Uterus</td>
<td>2006</td>
<td>3,367</td>
<td>26.4</td>
<td>7.5</td>
<td>33.8</td>
<td>32.2–35.5</td>
<td>14.8</td>
<td>13.6–16.0</td>
</tr>
<tr>
<td></td>
<td>2009</td>
<td>4,850</td>
<td>29.2</td>
<td>5.5</td>
<td>34.7</td>
<td>33.3–36.0</td>
<td>12.5</td>
<td>11.6–13.5</td>
</tr>
<tr>
<td>All other cancers</td>
<td>2006</td>
<td>5,280</td>
<td>27.2</td>
<td>7.0</td>
<td>34.3</td>
<td>33.0–35.6</td>
<td>14.6</td>
<td>13.7–15.6</td>
</tr>
<tr>
<td></td>
<td>2009</td>
<td>15,466</td>
<td>27.6</td>
<td>5.8</td>
<td>33.4</td>
<td>32.7–34.2</td>
<td>12.4</td>
<td>11.9–12.9</td>
</tr>
<tr>
<td>Total</td>
<td>2006</td>
<td>27,860</td>
<td>27.7</td>
<td>8.1</td>
<td>35.8</td>
<td>35.3–36.4</td>
<td>15.1</td>
<td>14.7–15.6</td>
</tr>
<tr>
<td></td>
<td>2009</td>
<td>48,831</td>
<td>29.9</td>
<td>6.0</td>
<td>35.9</td>
<td>35.4–36.3</td>
<td>12.6</td>
<td>12.3–12.9</td>
</tr>
</tbody>
</table>

*Imaging-adjusted impact: No benefit from PET was assumed for cases with a plan before PET of alternative imaging.

TABLE 4
Impact of PET on Intended Management During Chemotherapy Monitoring

<table>
<thead>
<tr>
<th>Cancer</th>
<th>Time period</th>
<th>Patients (n)</th>
<th>Continue therapy</th>
<th>Switch therapy</th>
<th>Adjust therapy</th>
<th>Image</th>
<th>Stop therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bladder</td>
<td>2006</td>
<td>1,089</td>
<td>283</td>
<td>310</td>
<td>402</td>
<td>72</td>
<td>237</td>
</tr>
<tr>
<td></td>
<td>2009</td>
<td>1,479</td>
<td>635</td>
<td>399</td>
<td>270</td>
<td>86</td>
<td>205</td>
</tr>
<tr>
<td>Kidney</td>
<td>2006</td>
<td>1,075</td>
<td>420</td>
<td>257</td>
<td>478</td>
<td>168</td>
<td>104</td>
</tr>
<tr>
<td></td>
<td>2009</td>
<td>1,934</td>
<td>1,015</td>
<td>478</td>
<td>247</td>
<td>106</td>
<td>92</td>
</tr>
<tr>
<td>Pancreas</td>
<td>2006</td>
<td>1,783</td>
<td>720</td>
<td>478</td>
<td>268</td>
<td>271</td>
<td>81</td>
</tr>
<tr>
<td></td>
<td>2009</td>
<td>2,198</td>
<td>1,103</td>
<td>550</td>
<td>250</td>
<td>151</td>
<td>98</td>
</tr>
<tr>
<td>Prostate</td>
<td>2006</td>
<td>1,024</td>
<td>348</td>
<td>261</td>
<td>255</td>
<td>145</td>
<td>69</td>
</tr>
<tr>
<td></td>
<td>2009</td>
<td>1,336</td>
<td>552</td>
<td>402</td>
<td>301</td>
<td>104</td>
<td>89</td>
</tr>
<tr>
<td>Small cell lung</td>
<td>2006</td>
<td>1,348</td>
<td>415</td>
<td>389</td>
<td>289</td>
<td>207</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td>2009</td>
<td>2,083</td>
<td>1,009</td>
<td>503</td>
<td>241</td>
<td>101</td>
<td>74</td>
</tr>
<tr>
<td>Uterus</td>
<td>2006</td>
<td>1,075</td>
<td>420</td>
<td>257</td>
<td>478</td>
<td>168</td>
<td>104</td>
</tr>
<tr>
<td></td>
<td>2009</td>
<td>1,113</td>
<td>455</td>
<td>313</td>
<td>281</td>
<td>71</td>
<td>64</td>
</tr>
<tr>
<td>All other cancer</td>
<td>2006</td>
<td>2,100</td>
<td>760</td>
<td>538</td>
<td>256</td>
<td>290</td>
<td>110</td>
</tr>
<tr>
<td></td>
<td>2009</td>
<td>4,387</td>
<td>2,047</td>
<td>1,121</td>
<td>256</td>
<td>284</td>
<td>198</td>
</tr>
<tr>
<td>Total cases</td>
<td>2006</td>
<td>10,234</td>
<td>3,554</td>
<td>2,735</td>
<td>1,492</td>
<td>1,901</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2009</td>
<td>15,611</td>
<td>7,315</td>
<td>4,049</td>
<td>2,574</td>
<td>2,547</td>
<td></td>
</tr>
</tbody>
</table>
be switched to another therapy in both the 2006 and the 2009 cohorts.

DISCUSSION

We have studied the CMS CED program for PET by comparing the NOPR 2006 and NOPR 2009 cohorts. In 2009, CMS provided coverage for nearly all primary cancers when PET was used in initial treatment management. Thus, in comparison to NOPR 2006, the ongoing NOPR 2009 program tracks a smaller group of cancers and primarily when PET is used for management other than the initial treatment strategy (i.e., for restaging and detection of suspected recurrence or for chemotherapy monitoring). We report data separately for the 7 most common cancer types in NOPR 2009, as well as for a remaining category encompassing “other solid tumors.” We have stratified the tumor-specific data based on the clinical indication for PET (restaging, detection of suspected recurrence, or chemotherapy monitoring) and the time period (before or after April 2009).

We found that when used for subsequent treatment planning, a NOPR PET scan was associated with about a 35% change in intended management. The observed intended management change was minimally different between cancer types, time periods (before or after 2009), and age (when comparing younger, disabled Medicare beneficiaries with the traditional Medicare population aged 65 y and over).

The imaging-adjusted impact of PET, calculated by assuming that a pre-PET plan of another type of imaging would have led to the same postimaging management plan as PET, showed a slight decline with time but was greater than 10% in all cancer types. As we have noted previously (8), the imaging-adjusted impact is a lower bound on the change in intended management, since a substantial body of literature shows that PET is more accurate—both more sensitive and more specific—than conventional cross-sectional imaging (11). The decline in imaging-adjusted impact from NOPR 2006 to NOPR 2009 is likely explained by referring physician’s gradually shifting their use of PET from a test done after body CT or MRI to one done in lieu of these other imaging methods. Therefore, some patients found to have extensive disease on CT previously would have undergone only CT, but such patients are now included in the PET group.

The role of PET in chemotherapy monitoring as a tool to measure therapy response as a guide to treatment adaptation is still evolving (12–14). Promising results have been reported in lymphoma, especially Hodgkin lymphoma (15). However, for solid tumors, there is little published information yet available about the impact of PET used for treatment adjustment during a planned course of therapy, nor is there consensus about when during a planned course of therapy PET should be done or standardization of the quantitative parameters (usually peak standardized uptake values) that should be assessed. Nonetheless, about 22% of NOPR 2009 scans were undertaken for chemotherapy treatment monitoring purposes.

To better assess this use of PET, in 2009 NOPR began collecting data on the duration of the current treatment at the time of a scan ordered for treatment monitoring. However, there are several limitations to the data. Although the concept of treatment monitoring is often assumed to require a baseline image for comparison, NOPR did not require that a preceding PET scan be available and we did not assess the rate or timing of prior scans in this study. About one third of patients had already received 6 mo or more of therapy. Therefore, it is uncertain whether these late scans could be alternatively classified as restaging rather than treatment monitoring. For this analysis, we used the classification reported by the referring physician.
We found that the principal impact of PET on management during chemotherapy occurred in patients whose PET scans showed more extensive disease or a worse prognosis than was anticipated. In these patients, the impact of imaging results was large and was consistent across cancer types and time intervals. Referring physician responses indicate that they planned to continue chemotherapy unchanged in only 10% of patients when PET indicated a worse prognosis than anticipated.

If referring physicians judged the post-PET prognosis to be better or unchanged, they intended to continue the current therapy more often in the NOPR 2009 cohort than in the NOPR 2006 cohort. We speculate that this decision was due to the use of PET earlier, on average, in the course of a planned treatment or to increased confidence in using PET to guide decision making.

CONCLUSION

Our analysis shows wide-ranging similarities across a broad spectrum of tumor types that are still being included in the Medicare CED process under NOPR 2009. The similarities across cancer subtypes were also robust to the study period (2006, 2009) and the indication for which a PET scan was ordered. To date, over 70,000 PET studies have been accrued for these cancers under NOPR 2009. There is little indication, either from the time series trend or from the type-specific data, that simply expanding the volume of scan data from further patients will provide much additional clinically meaningful insight into the impact of PET on intended management of these patients. A second key finding occurs when the present data are compared with our multiple prior publications on the NOPR 2006 cohort, where PET under CED was discontinued for many cancer types and indications in April 2009. There are few if any impactful differences between those types of patients (and cancers) now covered without CED and those remaining under the CED registry protocol.

Although PET has a primary and fundamentally accepted role in oncology today, there remain open questions as to how PET should be most effectively sequenced with other imaging resources in patient care pathways and what protocols will be most accurate and efficient when PET is used for chemotherapy monitoring. A paradigm different from that of the NOPR program will be necessary to better define plans that assess and compare care pathways that implement the available advanced imaging modalities for major decision points in cancer care. NOPR has been successful, however, in providing clear data on the previously little-researched question of whether the impact of PET on different cancers would be similar in actual clinical practice in the Medicare population. Even with less common cancers, the impact of PET on physician decision making for patient management seems remarkably uniform.

DISCLOSURE STATEMENT

The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

ACKNOWLEDGMENTS

Funding for development of the NOPR was provided by the Academy for Molecular Imaging, but the registry is otherwise self-supported by the fees paid by participating PET facilities. No other potential conflict of interest relevant to this article was reported.

REFERENCES